Neutral
Moderna Inc. is continuing to advance its mRNA-based vaccine and therapeutic pipeline, building on its success with the COVID-19 vaccine. The company'...
Neutral
Corient Private Wealth LLC increased its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 24.1% in the fourth quarter, according to its most r...
Neutral
Moderna (MRNA) stock soared 9.2% after a positive FDA advisory panel recommendation for its flu vaccine mRNA-1010/mFLUSIVA and promising updates on it...
Bullish
Moderna Inc. (MRNA) stock surged over 7% after its flu shot received unanimous FDA advisory backing and the company revealed significant pipeline prog...
Neutral
Moderna (MRNA) saw a significant stock price surge of 14.2%, reaching $68.23, driven by renewed investor confidence and positive developments in its m...
Bullish
Moderna Inc. (MRNA) stock surged over 11% following positive news regarding its mRNA vaccine pipeline, including a unanimous FDA advisory committee ba...
Bullish
Moderna showcased the continued expansion of its mRNA platform at its annual Science Day, emphasizing its pipeline across infectious disease vaccines,...
Neutral
Moderna (MRNA) stock surged 14% to $68, significantly outperforming Merck (MRK) and Pfizer (PFE), which gained 2% each. This rally is attributed to an...
Bullish
Moderna Inc. stock reached a new 52-week high of $67.78, reflecting a significant recovery and 145.18% increase over the past year, though InvestingPr...
Bullish
Moderna Inc. (MRNA) stock surged over 6% following several positive developments. Key drivers include a unanimous FDA advisory committee backing for i...
Bullish
Moderna's stock has surged over 100% this year, fueled by its mRNA technology and potential new product launches. Investors are anticipating a crucial...
Bearish
Moderna stock experienced a significant drop, ending a six-day winning streak and making it one of the S&P 500's worst-performing stocks today. This r...
Analysts have issued neutral ratings for healthcare companies AbbVie (ABBV) and Moderna (MRNA), indicating neither a bullish nor bearish outlook. UBS ...
Neutral
A Delaware federal court has permitted Moderna and Pfizer/BioNTech to assert prosecution laches as a defense in patent infringement lawsuits filed by ...
Bullish
Moderna's mRNA-based flu vaccine, mFlusiva, received unanimous support from the FDA's independent advisory panel for full approval in adults aged 50-6...
Bullish
Moderna's stock surged nearly 60% over five trading sessions after the FDA released briefing documents for its seasonal flu vaccine, mFlusiva, ahead o...
Moderna is considering acquiring BioNTech's German manufacturing plants that are slated for closure, according to CEO Stéphane Bancel. This move is co...
Bullish
Moderna, Inc. announced it will host an Investor Event - Science Day on Thursday, June 25, 2026, at 9:00 AM ET. The event will showcase the company's ...
Neutral
Moderna (MRNA) stock has seen a significant surge of 94% year-to-date in 2026, outperforming Pfizer (PFE) at 4% and Novavax (NVAX) at 41%. This growth...
Bullish
Moderna (MRNA) stock is gaining momentum, up 9.88% due to impressive five-year data for its personalized mRNA cancer vaccine combined with Keytruda, w...